Biomedica Immunoassays

525 €

Contact us!

Osteoprotegerin ELISA

Day test! - CE marked - for IVD use in EU.

PRODUCT DETAILS

Assay characteristics:

Cat.No.: BI-20403
Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
Sample type:Serum, plasma (EDTA, heparin, citrate)
Standard range:0-20 pmol/l (6 serum based standards) 
Standard points:0/1.25/2.5/5/10/20 pmol/l
Control:1 serum based control
Sample size:20 µl / well
Incubation time:4 h / 1 h / 30 min
Unit conversion:1 pg/ml = 0.05 pmol/l (MW: 19.9 kDa)

Sensitivity:
LOD: 0.07 pmol/l (0 pmol/l + 3 SD); LLOQ: < 0.08 pmol/l

Precision:
Intra-assay (n=5) ≤ 3%, Inter-assay (n=12) ≤ 5%

Spike/Recovery:
The mean recovery of recombinant OPG in serum and EDTA plasma is between 93-108%.
The mean recovery of recombinant OPG in heparin - and citrate plasma is between 82-109%.

Dilution linearity:
The dilution linearity of endogenous OPG in serum samples (n=3) is between 79-102%.
The dilution linearity of recombinant OPG in serum samples (n=8) is between 80-116%.

Cross reactivity: 
The assay does not cross react with rat or mouse samples. 

Values from apparently healthy individuals:
Median (serum, n=60): 2.7 pmol/l.  
It is recommended to establish the normal range for each laboratory. 

Principle of the assay: 



Manual ELISAs - easily adaptable for automation! 

Back to top

INSTRUCTIONS FOR USE

Click link for: 

BI-20403 OPG ELISA IFU

Biomedica Analytical Service Quotation Form

Back to top

VALIDATION DATA

Click here for assay validation data (S/R, dilution linearity, precision, ...).

 

 

Back to top

ADDITIONAL INFORMATION

Osteoprotegerin (OPG) or osteoclast inhibitory factor (OCIF) is a glycoprotein of the TNF receptor superfamily 11b (gene name TNFRSF11B, http://www.uniprot.org/uniprot/O00300). OPG is synthesized as a monomer of 380 amino acids and is assembled as a homodimer within the cell, and then secreted mainly as a disulfide-linked homodimer into the extracellular compartment. OPG is produced by many different tissues and cell types including osteoblasts. OPG is a negative regulator of bone resorption by acting as decoy receptor for RANKL, thus neutralizing its function in osteoclastogenesis. This glycoprotein is also involved in the regulation of vascular calcification.

Click here for MSDS
Click here for PRODUCT LEAFLET
Click here for OPG - a BIOMARKER in CARDIOLOGY
Click here for BIOMARKER in CLINICAL NEPHROLOGY

Back to top

REFERENCES, APPLICATIONS

Click here for reference list.

Click here for OPG in Renal Disease.
Click here for OPG - a Biomarker in Cardiology

Back to top